Table 2 Comparison of treatment eligibility criteria among treatment-naïve chronic hepatitis B patients, Ethiopia (N = 271)
St. Paul | EASL 2012 | EASL 2017 | WHO 2015 | ||||
|---|---|---|---|---|---|---|---|
Criteria | N | Criteria | N | Criteria | N | Criteria | N |
Decompensated cirrhosis | 20 | Cirrhosis and detectable VL | 40 | Cirrhosis and detectable VL | 40 | Decompensated cirrhosis | 20 |
Compensated cirrhosis | 20 | Significant fibrosis and VL >2000 IU/ml | 8 | Significant fibrosis and VL >2000 IU/ml | 8 | APRI >2.0a | 4 |
Significant fibrosis and VL >2000 IU/ml | 8 | ALT >80 U/L and VL >20,000 IU/ml | 1 | ALT >80 U/L and VL >20,000 IU/ml | 1 | Age ≥ 30 years and ALT >40 U/L and VL >20,000 IU/ml | 5 |
ALT >80 U/L and VL >2000 IU/ml | 3 | Metavir ≥A2 and VL >2000 IU/mlb | 0 | Metavir ≥A2 and VL >2000 IU/mlb | 0 | ||
Family history HCC and VL >2000 IU/ml | 5 | HBeAg positive and age ≥ 30 years | 3 | ||||
Family history HCC or cirrhosis | 16 | ||||||
Total | 56 | Total | 49 | Total | 68 | Total | 29 |